SLU-PP-332 is an agonist of ERRα and ERRγ receptors that activates the same mitochondrial gene expression programs as endurance exercise — nicknamed an exercise mimetic for its ability to improve oxidative capacity and endurance without physical activity.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
SLU-PP-332 was developed at Washington University School of Medicine and identifies as a potent agonist of the Estrogen-Related Receptors alpha and gamma (ERRα and ERRγ) — nuclear receptor transcription factors that function as master regulators of mitochondrial biogenesis and oxidative metabolism. In muscle tissue, ERR activation drives the same gene expression profile that endurance exercise training produces: upregulation of genes encoding mitochondrial electron transport chain components, fatty acid oxidation enzymes, and slow-twitch (oxidative) muscle fiber proteins. The result is improved metabolic efficiency and endurance capacity even in the absence of training.
Mechanism of Action
SLU-PP-332 binds and activates ERRα and ERRγ, which are constitutively active nuclear receptors that regulate gene expression without requiring a ligand under normal circumstances — but whose activity is greatly amplified by agonist binding. Activated ERRs drive transcription of PGC-1α target genes including NRF1, TFAM, COX subunits, and fatty acid oxidation enzymes. This produces: increased mitochondrial content in skeletal muscle, a shift from fast-twitch glycolytic fibers to slow-twitch oxidative fibers (more efficient, more fatigue-resistant), enhanced fat oxidation rate, and improved VO2max in rodent models. SLU-PP-332 also activates cardiac ERRs, potentially offering cardioprotective metabolic effects.
Key Research
SLU-PP-332 was developed and studied at Washington University in St. Louis (Bhatt et al., 2023, Cell Reports). Published data in aged mice demonstrated 70% improvement in running endurance, increased mitochondrial content in skeletal muscle, and shift to oxidative fiber phenotype after 28 days. Untrained mice treated with SLU-PP-332 showed endurance capacity approaching that of exercise-trained controls. Additional unpublished institutional data reportedly showed cardiac protection in metabolic disease models. No human clinical trials have been initiated. The compound is at early preclinical stage — human dose has not been established.
5–30 mg/kg in animal research; human dose not established
Half-Life
~4–6 hours (estimated)
No human dose has been established for SLU-PP-332. Research community protocols extrapolate from rodent data using allometric scaling: approximately 5–15 mg total daily dose for a 70 kg human as a rough estimate. Early research protocols typically use the lowest effective dose with gradual increases and close monitoring. Oral administration is the primary route in animal studies. This is an early-stage research compound — human use should be treated with appropriate caution given the absence of human safety data.
Performance Research Protocol: SLU-PP-332 (dose TBD based on ongoing human research) orally combined with MOTS-c 5 mg SC 3x weekly for combined exercise mimetic and mitochondrial biogenesis effects. Longevity Stack: SLU-PP-332 + Humanin 2 mg SC 3x weekly + Epithalon pulse for ERR-driven metabolic optimization alongside telomere and mitokine support.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
No human safety data is available. Animal studies showed good tolerability at effective doses with no significant organ toxicity identified in acute rodent studies. Theoretical concerns include: excessive shift to oxidative fiber phenotype reducing explosive (fast-twitch) performance; potential cardiac effects from altered ERR signaling in heart tissue; and off-target effects via related nuclear receptors (ERRβ, ERα). These concerns are theoretical based on mechanism and have not been observed in preclinical data. Given the absence of human data, this compound should only be used in formal research contexts with appropriate monitoring.
Storage & Handling
Research-grade compound. Store lyophilized or crystalline SLU-PP-332 at -20°C, protected from light and moisture. Stable for up to 12 months under proper conditions. For solution preparation, DMSO or ethanol may be needed for initial dissolution before dilution in aqueous vehicle. Handle under inert conditions if possible. Oral preparation: dissolve in an appropriate carrier for gavage or capsule administration.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
